Clinical Trials

MyeloidOther hematologic neoplasm

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06317649 2026-03-18

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

147 enrolled

Leukemia, Myeloid, Acute

NCT06222580 2026-03-13

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

30 enrolled

Phase 3 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07463651 2026-03-11

TROPHY-15

594 enrolled

Leukemia, Myeloid, Acute

NCT05756777 2026-03-05

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

36 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

70 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT07140016 2026-03-04

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Phase 3 Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07407140 2026-03-02

VAG-3+7-G

300 enrolled

Leukemia, Myeloid, Acute

NCT04293562 2026-02-24

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3 Recruiting

1,186 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03182244 2026-02-06

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

276 enrolled 41 charts

Leukemia, Myeloid, Acute

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

125 enrolled

Leukemia, Myeloid, Acute

NCT04240002 2026-01-05

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

9 enrolled 21 charts

Leukemia, Myeloid, Acute

NCT07032727 2025-12-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

68 enrolled

Targeted Therapy

NCT05955261 2025-12-09

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04140487 2025-12-05

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 1/2 Recruiting

97 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

371 enrolled 36 charts 2 FDA

Leukemia, Myeloid, Acute

NCT06001788 2025-12-03

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06235801 2025-11-19

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase 1/2 Recruiting

20 enrolled

Leukemia, Myeloid

NCT06225427 2025-10-20

Gilteritinib for the Treatment of ALK NSCLC

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Phase 3 Completed

183 enrolled 30 charts

Leukemia, Myeloid, Acute

NCT06734585 2025-09-12

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Completed

114 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02310321 2025-09-02

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Phase 1/2 Completed

97 enrolled 30 charts

Leukemia, Myeloid, Acute

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06992934 2025-08-03

TARGETALLO

10 enrolled

Phase 2 Active not recruiting

Hematologic Neoplasms

NCT03836209 2025-06-15

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

181 enrolled 18 charts

Leukemia, Myeloid, Acute

NCT04691648 2025-05-31

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Completed

33 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06696183 2025-05-29

SEQUENCE

60 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04988555 2025-04-02

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Phase 1/2 Recruiting

362 enrolled

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06022003 2025-03-24

OGILAR

33 enrolled